Global Kinase Inhibitors Market Report 2021-2026Featuring Major Players - Pfizer, Novartis, AstraZeneca, Bayer, Eisai and Johnson & Johnson
Dublin, July 02, 2021 (GLOBE NEWSWIRE) -- The "Global Kinase Inhibitors Market 2021-2026" report has been added to ResearchAndMarkets.com's offering.
The global market for kinase inhibitors should grow from $57.6 billion in 2021 to $79.2 billion by 2026 with a compound annual growth rate (CAGR) of 6.6% for the period of 2021-2026.
This report is designed to be a business tool that will provide a thorough evaluation of the markets for kinase inhibitors. The geographical scope of this study is global. Various types of kinase inhibitors have been analyzed in the report, and along with their different application scenarios, the scope of this study includes regulatory aspects, pipeline analysis and demand for kinase inhibitors. The report discusses market shares of kinase inhibitors based on type, application and geography.
The dynamic field of cancer R&D is allowing an enhancement to the specialization in kinases, which play a crucial role as mediators in many sorts of cancer and other diseases, and also demonstrate a pivotal role in modulating diverse cellular activities.
The market for kinase inhibitor market is experiencing an increasing demand for a number of novel kinase inhibitors being utilized in human trials. The kinase inhibitor field is seeing a rise in the development of next-generation inhibitors that focus on cancers and other diseases, including inflammation. As the field of kinase inhibitors matures, market leaders are trying to answer questions regarding technologies and methods used or in reference to novel targets and therapeutic approaches concerning kinase inhibitors.
The growth of the global market is attributed to factors such as the growing prevalence of cancer and other chronic diseases, and strong investment in R&D activities by key market players. Pfizer and Novartis are the leaders in the kinase inhibitor market. Companies are investing in research to deal with issues such as resistance, selectivity vs. safety, developing lead compounds, integrating chemistry and biology into development, and utilizing the newest techniques, such as fragment- and structure-based design, to develop new products.
The presence of pharmaceutical giants in this region, a developed regulatory and healthcare infrastructure, and stronger intellectual property protection are favorable factors for the growth of the U.S. market for kinase inhibitors. The rising prevalence of many chronic diseases along with growing aging population also drives the market in the U.S. and Europe, particularly the U.K.
However, the decision of the U.K. government to exit the E.U., aka Brexit, might prove a deterrent for investors in the U.K. market for enzyme inhibitors. The emerging markets, particularly the Asia-Pacific region, have shown growth potential in recent years. The rising affluence in these countries has brought a change in the lifestyles of the populations, which have resulted in increased incidences of diseases such as cancers and immunological disorders.
Countries in Africa and other developing countries are still battling with some of the highest proportions of immune-mediated diseases. The need for affordable and innovative medicines is the growth driver for the kinase inhibitor market in the low- and middle-income developing countries of the emerging markets.
The Report Includes
Estimation of the market size and analyses of global market trends, with data from 2019, 2020 estimates for 2021 and projections of compound annual growth rates (CAGRs) through 2026
Identification of market drivers, restraints and other forces impacting the global market and evaluation of current market size and forecast and technological advancements within the industry
Information on enzyme inhibitors, kinase inhibitors and classification by types of amino acid & phosphorylation
Analysis of pipeline products and kinase inhibitors related patents, and comparative description of multiple single kinase inhibitors versus single multi-kinase inhibitors in terms of efficacy, resistance and pharmacokinetics
Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
Company profiles of major players, including Pfizer, Novartis AG, AstraZeneca, Bayer AG, Eisai Co. Ltd. and Johnson & Johnson
Key Topics Covered:
Chapter 1 Introduction
Chapter 2 Summary and Highlights
Chapter 3 Market and Technology Background
Definitions
Enzymes
Coenzymes
Enzyme Inhibitors
Active Site
Enzyme Inhibitors
Why Enzyme Inhibition?
Use of Enzyme Inhibitors
Mechanism of Enzyme Inhibition
Types of Enzyme Inhibitors
Classification of Enzyme Inhibitors
Kinase Inhibitors
History of Protein Kinases
Type of Kinase Inhibitors
Classification by Types of Amino Acid Phosphorylation
Classification by Site of Action
Market Dynamics
Chapter 4 Covid Impact on Market
Short-Term Impact on Pharmaceutical Industry
Long-Term Impact
Current Outlook
COVID-19 Impact on Cancer Care
Chapter 5 Regulatory Scenario
Market Leaders and Their Products for Kinase Inhibitors
Chapter 6 Market Breakdown by Type
Introduction
Tyrosine Kinase Inhibitors
Market Size and Forecast
Market Analysis
Serine/Threonine Kinase Inhibitors
mTOR Kinase Inhibitors
B-Raf
RHO Kinase Inhibitors
Cyclin-Dependent Kinase Inhibitors
Aurora Kinase Inhibitors
MAP/MEK Kinase Inhibitors
JNK Inhibitors
Protein Kinase C Inhibitors
PI3K Inhibitors
Market Size and Forecast
Market Analysis
Chapter 7 Market Breakdown by Application
Introduction
Antineoplastic Agents
Market Size and Forecast
Market Analysis
Age-related Macular Degeneration (AMD)
Market Size and Forecast
Market Analysis
Immunosuppressant
Market Size and Forecast
Market Analysis
Chapter 8 Market Breakdown by Region
Chapter 9 Industry Developments
Company Share Analysis
Pipeline Analysis
Patent Analysis
Current Scenario
Cancer and Kinase Inhibitors
Multiple Single Kinase Inhibitors Vs. Single Multi-kinase Inhibitors
Efficacy
Resistance
Pharmacokinetics
Selectivity
Tumor Microenvironment
Toxicity
Future Directions
Chapter 10 Company Profiles
Leading Companies
Astrazeneca
Bayer Ag
Boehringer Ingelheim International Gmbh
Bristol-Myers Squibb
Eisai Co. Ltd.
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Novartis Ag
Pfizer
Other Manufacturers
Astellas Pharma Inc.
Aveo Pharmaceuticals, Inc.
Exelixis Inc.
Merck Kgaa
Sanofi
Takeda Pharmaceutical Co., Ltd.
Chapter 11 Appendix A: Abbreviations and Acronyms
For more information about this report visit https://www.researchandmarkets.com/r/bba4t4
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900